Abstracts Archive - Page 29 of 2616 - ACR Meeting Abstracts

Abstract Number: 0351 • ACR Convergence 2025
Experience with romosozumab in women with osteoporosis at high risk of fracture in real-world clinical practice
MARIA DEL CARMEN ORTEGA DE LA O¹, Laura Gonzalez Hombrado², Marina Salido Olivares³, Carolina Marin⁴, Angel Aragon⁵, Celia arconada⁶, Maria Carmen Ortega de la O⁷, Alvaro Garcia⁸, elisabeth Castañeda⁹, Patricia Castro Perez¹⁰, alberto diaz Oca¹¹ and Eva Andres Esteban¹², ¹HOSPITAL UNIVERSITARIO GETAFE, GETAFE, Madrid, Spain, ²Hospital Universitario del Tajo, Aranjuez (MADRID), Madrid, Spain, ³Hospital Clinico San Carlos, Madrid, Madrid, Spain, ⁴Hospital Infanta Leonor, Madrid, Madrid, Spain, ⁵Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain, ⁶Hospital universitario de Getafe, Getafe, Madrid, Spain, ⁷Hospital Universitario Getafe, Madrid, Madrid, Spain, ⁸Hospital Universitario del Tajo, Aranjuez, Madrid, Spain, ⁹Hospital Universitario Infanta Sofía, Madrid, Madrid, Spain, ¹⁰Hospital de Getafe, Madrid, Madrid, Spain, ¹¹Hospital de Fuenlabrada, Fuenlabrada, Madrid, Spain, ¹²Universidad Rey Juan Carlos, Fuenlabrada, Spain
Background/Purpose: Romosozumab (RMZ) is a recently approved dual-acting drug which has been shown to reduce fracture risk in patients with osteoporosis (OP) in clinical trials.…
Abstract Number: 0230 • ACR Convergence 2025
An Epic journey – Therapeutic Drug Monitoring at an Academic Center
Puja Khanna¹ and Michael Rice², ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Gastroenterology, University of Michigan, Ann Arbor, MI
Background/Purpose: Non-oncologic use of immunomodulatory agents is increasing. These drugs have a narrow, patient-specific therapeutic index, making therapeutic drug monitoring essential for safe prescribing. However,…
Abstract Number: 0323 • ACR Convergence 2025
Automated Effusion-Synovitis Volume is Prognostic and Responsive to Knee Osteoarthritis Progression: Data from the Osteoarthritis Initiative
Jeffrey Driban¹, Kate Lapane², Shao-Hsien Liu², Jonggyu Baek², Grace Lo³, Matthew Harkey⁴, Charles Eaton⁵, James Mackay⁶, Timothy McAlindon⁷, Mohammad Chowdhury⁸, Zhen Cao⁹, Juan Shan¹⁰ and Ming Zhang¹¹, ¹University of Massachusetts Chan Medical School, Marlborough, NH, ²UMass Chan Medical School, Worcester, MA, ³Baylor College of Medicine / MEDVAMC, Houston, TX, ⁴Michigan State University, East Lansing, MI, ⁵Brown University, Pawtucket, RI, ⁶University of Cambridge; Norwich Medical School, San Diego, CA, ⁷UMass Chan School of Medicine, Arlington, MA, ⁸Pace University, New York City, NY, ⁹Boston University, Boston, MA, ¹⁰Pace University, New York, NY, ¹¹Boston University, Westford, MA

Background/Purpose: Semi-quantitative and semi-automated quantitative measurements of effusion-synovitis (ES) are prognostic for knee OA progression. Changes in these metrics relate to changes in knee pain.…
Abstract Number: 0330 • ACR Convergence 2025
Prevalence of Radiographic and Symptomatic Osteoarthritis, and Ultrasound Features at the Knee: The Johnston County Health Study
Maya Patel¹, Carolina Alvarez², Todd Schwartz³, Tessa Walker¹, Serena Savage-Guin¹, Jordan Renner¹, Jonathan Samuels⁴, Janice Lin⁵, Minna Kohler⁶, Catherine Bakewell⁷, Yvonne Golightly⁸ and Amanda Nelson¹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Miami, FL, ³University of North Carolina-Chapel Hill, Chapel Hill, NC, ⁴NYU Langone, Rye Brook, NY, ⁵Stanford University, Palo Alto, CA, ⁶Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁷Intermountain Healthcare, Salt Lake City, UT, ⁸University of Nebraska Medical Center, Omaha, NE
Background/Purpose: To report sex and BMI differences among ultrasound (US) features of knee osteoarthritis (KOA), patient-reported symptoms (Ksx), radiographic KOA (rKOA), and symptomatic KOA (sxKOA),…
Abstract Number: 0319 • ACR Convergence 2025
Glucagon-like Peptide-1 Receptor Agonists in Management of Knee Osteoarthritis: A Meta-Analysis
Danielle Madison¹, Adriana Morales Rivera², Dylon Collins², Isabel Lam², Daniel Khokhar², Garrett Snyder², Anthony Thompson², Mark Soliman², Daniela Carralero Somoza² and Michael Sabina², ¹Lakeland Regional Medical Center, Lakeland, FL, ²Lakeland Regional Medical Center, Lakeland
Background/Purpose: Knee osteoarthritis (KOA) is a leading cause of disability and the most common rheumatological condition worldwide. Weight management has been recognized as a key…
Abstract Number: 0374 • ACR Convergence 2025
Assessing Attitudes and Barriers to Vaccination in Pediatric Rheumatic
Merav Heshin Bekenstein¹, Rebecca Hetrick², Vidya Sivaraman³, Beth Rutstein⁴, Albert Chow⁵, Peter Chiraseveenuprapund⁶, Vincent Del Gaizo⁷, Melanie Kohlheim⁸, guy Brock⁹, Sapuni Chandrasena⁹, Chloé Janse van Rensburg¹⁰ and Marina Gad El Sayed¹¹, ¹Tel Aviv Medical Center Israel, Binyamina, Tel Aviv, Israel, ²Indiana University School of Medicine, Indianapolis, IN, ³Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ⁴The Children's Hospital of Philadelphia, Wynnewood, PA, ⁵Loma Linda University, Loma Linda, CA, ⁶University of Utah, Salt Lake City, UT, ⁷Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, ⁸CARRA, Granville, OH, ⁹The Ohio State University Wexner Medical Center, Columbus, OH, ¹⁰Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada, ¹¹University of California, Riverside School of Medicine, Riverside, CA
Background/Purpose: Vaccine-preventable diseases pose greater risk to children with rheumatic diseases treated with immunosuppressive therapies and to those with underlying immune dysregulation. Despite the importance…
Abstract Number: 0314 • ACR Convergence 2025
What changes in quality of life can be observed in patients with knee or hip OA prior to total hip or total knee replacement surgery ? data from the KHOALA cohort
Anne-Christine Rat¹, LATOURTE Augustin², Maud Wieczorek³, Jérémie sellam⁴, willy Ngueyon Sime⁵, Jacques Pouchot⁶, Christian Roux⁷, Alain SARAUX⁸, Francis Guillemin⁹ and Joel Coste¹⁰, ¹Caen University hospital, UMR ¹⁰⁷⁵ Caen normandy university, Caen, France, ²Rheumatology Department, Lariboisiere Hospital, Paris, France, ³Lausanne Univserty, Lausanne, Switzerland, ⁴Saint-Antoine hospital, Assistance Publique – Hôpitaux de Paris, Paris, France, Sorbonne University, Paris, France, ⁵CIC, Epidémiologie Clinique, CHRU-Nancy, Inserm, Université de Lorraine, Nancy, France, nNancy, France, ⁶HEGP hospital, Assistance Publique-Hopitaux de Paris,, Paris, France, ⁷CHU Nice, Nice, France, ⁸CHU Brest, Brest, France, ⁹CHU Nancy, Nancy, France, ¹⁰, Assistance Publique – Hôpitaux de Paris, Paris, France
Background/Purpose: Few studies have examined how the quality of life (QoL) evolves in patients with osteoarthritis (OA) before undergoing total hip or total knee replacement…
Abstract Number: 0235 • ACR Convergence 2025
Mortality Trends due to Hypertension Related Deaths in Elderly Patients with Inflammatory Polyarthropathy: A CDC WONDER Analysis of 21 Years
ZAUHA FAWAD MEMON¹, Sibgha Fawad Memon², Matia Fawad Memon², REHAN ISHAQUE³, AHMAD SANAN⁴ and MUHAMMAD MUGHEES⁵, ¹Peoples University of Medical and Health Sciences for Women, Tando Allahyar, Sindh, Pakistan, ²Peoples University of Medical and Health Sciences for Women, Tando Allahyar, Pakistan, ³LIAQUAT UNIVERSITY OF MEDICAL AND HEALTH SCIENCES, Jam Shoro, Sindh, Pakistan, ⁴KHYBER MEDICAL COLLEGE, Peshawer, Pakistan, ⁵Bahria University health Sciences, KARACHI, Pakistan
Background/Purpose: Inflammatory polyarthropathy (IPA) is a group of chronic autoimmune disorders, common among older adults and contribute significantly to systemic inflammation and cardiovascular risk .…
Abstract Number: 0243 • ACR Convergence 2025
Epidemiology of adult-onset Systemic Autoinflammatory Diseases in a well-defined population from northern spain
Carmen Lasa Teja¹, Laura Muñoz-Llopis², Diana Prieto-Peña³, Isla Morante Bolado⁴, José Luis Martín-Varillas⁵, Nerea Paz-Gandiaga⁶ and Ricardo Blanco⁷, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ⁴Rheumatology, Hospital General Sierrallana, Torrelavega, Spain., Santander, ⁵Rheumatology Division, Hospital de Laredo. IDIVAL, Immunopathology Group. Santander, Spain., Laredo, Spain, ⁶Rheumatology, Hospital Comarcal de Laredo, Laredo, Spain., Santander, ⁷Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Systemic autoinflammatory diseases (SAIDs) are rare disorders characterized by recurrent episodes of fever, serositis, gastrointestinal symptoms, arthritis, and/or skin lesions. In adult-onset SAIDs, clinical…
Abstract Number: 0194 • ACR Convergence 2025
Evaluation of a Home-based Therapeutics Service: Feasibility, Patient and Caregiver Experience, and Cost
Xiaohui Xin, Andrea Low, Sow Ling Yee, Miao Miao Liu, Christina Tan, Daphne Ng and Siaw Ing Yeo, Singapore General Hospital, Singapore, Singapore
Background/Purpose: The home-based therapeutics service (HTS) by a community nurse is part of an ongoing larger initiative—Community Therapeutics Programme (CTP)—spearheaded by the Rheumatology and Immunology…
Abstract Number: 0232 • ACR Convergence 2025
Hydroxychloroquine Blood Testing in Lupus: The Michigan Medicine Experience
Zeinab Saleh¹, Michelle Kahlenberg², Wendy Marder¹ and Emily Somers¹, ¹University of Michigan, Ann Arbor, MI, ²Michigan Medicine, Ann Arbor, MI
Background/Purpose: Measuring hydroxychloroquine (HCQ) blood levels in patients with systemic lupus erythematosus (SLE) can assess medication adherence and determine whether concentrations fall within the therapeutic…
Abstract Number: 0250 • ACR Convergence 2025
Autoinflammatory diseases in adult patients. Spanish registry.
Eztizen Labrador-Sanchez¹, Diana Prieto-Peña², Carlota L Iñiguez³, Rafael B. Melero-González⁴, Alberto Ruiz-Roman⁵, Clara Moriano⁶, Paula García-Escudero⁷, Anahy Maria Brandy⁸, Marta López⁹, Fred Anton Pages¹⁰, Maria Camila Osorio-SanJuan¹¹, Nahia Plaza-Aulestia¹², Bryan Josué Flores Robles¹³, Estibaliz Andres Trashaedo¹⁴ and Ricardo Blanco¹⁵, ¹Hospital Universitario San Pedro, Laguardia, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ³Hospital del Bierzo, Ponferrada, Castilla y Leon, Spain, ⁴COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ⁵Hospital Juan Ramon Jimenez, Huelva, Spain, ⁶Hospital León, LEON, Castilla y Leon, Spain, ⁷Hospital Universitario Álava, Bilbao, Spain, ⁸Hospital Germans Trias i Pujol, Badalona, Spain, ⁹Complex Hospitalari Universitari Moisés Broggi, Barcelona, Spain, ¹⁰Hospital General de Segovia, Segovia, Spain, ¹¹Hospital Clínico Lozano Blesa, Zaragoza, Spain, ¹²Rheumatology division. Galdakao-Usansolo University Hospital, Galdakao, Spain, ¹³Hospital San Pedro, Logroño, Spain, ¹⁴Hospital San Pedro, Logroño, Spain, ¹⁵Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Autoinflammatory diseases(AIDs) are characterized by recurrent inflammatory episodes resulting from alterations in regulatory genes, activating the innate immune system. Although these diseases primarily occur…
Abstract Number: 0282 • ACR Convergence 2025
Clinical Meaningfulness and Improvement Thresholds of Myositis Core Set Measures: Association with Patient-Reported Outcomes
Shiri Keret¹, Raisa Lomanto Silva², Irada Choudhuri³, Eugenia Gkiaouraki³, Tanya Chandra³, Nantakarn Pongtarakulpanit³, Shreya Sriram³, Niladri Bhowmick³, Vaidehi Kothari³, Kaushik Sreerama Reddy³, Eaman Alhassan⁴, Anushka Aggarwal⁵, Maha Almackenzie⁶, Siamak Moghadam-Kia⁴, Dana Ascherman⁷, Chester V. Oddis⁷ and Rohit Aggarwal⁸, ¹Bnai Zion Medical Center, Atlit, Israel, ²Massachusetts General Hospital, Boston, MA, ³University of Pittsburgh Medical Center, Pittsburgh, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Indraprastha Apollo Hospital, New Delhi, India, ⁶Medical Cities of the Ministry of the Interior, Riyadh, Saudi Arabia, ⁷University of Pittsburgh, Pittsburgh, PA, ⁸University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: The six myositis core set measures (CSMs) are widely utilized to assess disease activity in idiopathic inflammatory myopathies (IIM). However, their association with how…
Abstract Number: 0255 • ACR Convergence 2025
Clearing the Smoke: Association Between Cannabis Use and Autoimmune Disease Incidence in a Retrospective Cohort Analysis
Justin Riley Lam¹, Emmanuel Otabor², Laith Alomari², Esteban Kosak Lopez², Maxim Barnett² and Shahrzad Abdollahi³, ¹Albert Einstein Medical Center, Philadelphia, PA, ²Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, ³Jefferson Einstein Hospital, Philadelphia, PA
Background/Purpose: Cannabis use has increased substantially in the past decades, with legalization expanding across the U.S. Despite its known therapeutic potential, the immunomodulatory effects of…
Abstract Number: 0297 • ACR Convergence 2025
Longitudinal Serum Proteomic Profiles – A Step Closer to Personalized Monitoring in Dermatomyositis
Natasha Le Blanc¹, Marie Hudson¹, Ana Cristina Gonzalez Sanchez², Lina Marcela Diaz Gallo² and Valerie Leclair³, ¹McGill University, Montréal, QC, Canada, ²Karolinska Institutet, Stockholm, Sweden, ³McGill University, Montréal, Canada
Background/Purpose: Dermatomyositis (DM) is a multisystemic immune mediated disease presenting with heterogeneous clinical features. Disease monitoring in DM relies in part on biomarkers of muscle…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].